ADMA Biologics, Inc.
↗Ramsey, New Jersey, United States
ADMA Biologics is an end-to-end commercial biopharmaceutical company specializing in the development, manufacturing, and marketing of specialty plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases. Founded in 2004, the company operates a vertically integrated business model with FDA-licensed plasma collection centers (ADMA BioCenters subsidiary) providing raw material for its manufacturing facility. The company is publicly traded on the NASDAQ under ticker symbol ADMA and has demonstrated exceptional growth, achieving 65% year-over-year revenue growth in 2024.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Specialty Biologics - Plasma-Derived Products
SIZE & FINANCIALS
Employees:501-1000
Revenue:$426.5M (2024)
Founded:2004
Ownership:public
Status:operating
FUNDING
Stage:N/A - Public Company
STOCK
Exchange:NASDAQ
Ticker:ADMA
Market Cap:$4.26B
PIPELINE
Stage:Commercial + Preclinical
Lead Drug Stage:Commercial (ASCENIV, BIVIGAM, NABI-HB)
Modalities:Plasma-derived biologics, Immune globulin intravenous (IVIG), Hyperimmune globulin
Active Trials:7
Trial Phases:Phase 3: 1
FDA Approvals:3
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:ADMA BioCenters (FDA-approved source plasma collection network)
Key Partnerships:Ares Management, KPMG LLP (operational efficiency consulting), Third-party high-titer plasma suppliers (approximately 250 collection centers)
COMPETITION
Position:Challenger
Competitors:CSL Behring (CSL Ltd) - Privigen, Hizentra, Grifols - Gamunex-C, Flebogamma, Takeda Pharmaceutical (acquired Shire/Baxalta) - Gammagard Liquid, Octapharma - Octagam, Panzyga, Emergent BioSolutions - HepaGam B (HBIG competitor)
LEADERSHIP
Key Executives:
Adam S. Grossman - President, Chief Executive Officer, Interim Chief Financial Officer, Director
Steven A. Elms - Chairman and Director
Kaitlin Kestenberg - Chief Operating Officer and Senior Vice President of Compliance
Dr. Jerrold B. Grossman - Vice Chairman and Director
Scientific Founders:Dr. Jerrold B. Grossman, Adam S. Grossman
Board Members:Steven A. Elms (Chairman), Adam S. Grossman (President & CEO), Dr. Jerrold B. Grossman (Vice Chairman), Bassem Guiheen (extensive plasma/pharma experience), Young T. Kwon, PhD (strategic/financial experience), Eduardo Rene Salas (joined December 2024)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ADMA Biologics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.